Organic Solvents May Explain Rise in NHL Among Women

Research carried out by the Yale School of Public Health and published in the American Journal of Epidemiology suggests that the 3-4% annual rise in incidence of non-Hodgkin lymphoma (NHL) over the last few decades may be at least in part due to exposure to organic solvents while working at a job that, for instance, requires using pesticides, embalming fluids, or places such as dry cleaning facilities.



By definition, an organic solvent contains carbon. Researchers looked at 601 women with NHL compared to 717 women without NHL and found that on-the-job exposure to:



Chlorinated solvents (organic solvents with chlorine) raised the risk of NHL by 40%

Formaldehyde exposure raised the risk by 30%

Carbon tetrachloride and benzene (both organic solvents and known human carcinogens) also raised the risk, although figures weren’t provided.



The researchers concluded that "these results support a potential association between occupational exposure to organic solvents and the risk of NHL among women.”

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap